drugset / Trial / NCT07572552

Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis

NCT07572552

Phase 2 Not yet recruiting 66 enrolled Tanta University
RandomizedParallel-groupOpen-labelOther

Summary

Sepsis is a life-threatening condition defined by organ dysfunction resulting from the body's dysregulated response to an infection (1). It begins with widespread inflammation and cellular damage, which quickly escalates into total circulatory failure and the breakdown of essential organ systems, including the lungs, kidneys, digestive tract, and brain. This study aims at evaluating the safety and efficacy of fenofibrate versus silymarin for adult patients with sepsis.

Timeline

Start
2026-05
Primary completion
2027-04
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 145 mg
Subject Silymarin Traditional medicine (herbal / TCM) 980 mg
Subject Silymarin Traditional medicine (herbal / TCM) 1120 mg